Changi General Hospital in Singapore has announced the initiation of a new clinical trial aimed at exploring the possibility of using a surgical technique to treat Alzheimer's disease. The trial, known as Cervical Lymphovenous Bypass for Alzheimer's Disease (CLyVeB-AD-1), targets four patients suffering from Alzheimer's, with the procedure conducted in January 2025.
This technique is based on the lymphatic system in the body, which serves as a pathway for clearing waste from the body, utilizing cerebrospinal fluid to help "flush" metabolic waste such as proteins associated with Alzheimer's, especially during deep sleep.
Details of the Procedure
The procedure involves connecting lymphatic structures, such as lymph nodes on either side of the neck, to adjacent veins to improve the drainage of protein-carrying fluids. Clinical Assistant Professor Vincent Tai, who leads the trial, explained that these surgical principles aim to create alternative pathways for fluid drainage, which may help eliminate the toxic proteins that accumulate in Alzheimer's disease.
The multidisciplinary team participating in the trial traveled to Hangzhou in China, where this technique was first used to treat Alzheimer's, to learn more about the method. The team received approval from the Institutional Review Board and the trial has been officially registered.
Background & Context
Approximately 100,000 people in Singapore are living with dementia, with Alzheimer's being the most common type, accounting for about 70% of cases. Currently, available medical treatments are limited to slowing the progression of the disease, making the need to explore innovative therapeutic methods urgent.
Current treatments include monoclonal antibodies, which have proven effective in slowing disease progression but come with side effects and require continuous monitoring. While older drugs do not alter the course of the disease, they help alleviate symptoms.
Impact & Consequences
Initial results from the trial indicate improvements in memory, mood, and cognitive abilities among the four patients who underwent the procedure. Brain scans have shown continued improvement after six months post-surgery, which may suggest stabilization of the condition.
Doctors reported that one patient, who had long suffered from depression and anxiety, became less anxious and showed an improved mood following the procedure. Another patient, who faced communication challenges, became more interactive and expressive after the surgery.
Regional Significance
This development in Alzheimer's treatment represents a significant step in the field of neurology and may open new avenues for therapy in Arab countries facing similar challenges with rising dementia rates. The adoption of such techniques could contribute to improving the quality of life for patients and their families.
In conclusion, this trial in Singapore emerges as a new hope in the fight against Alzheimer's disease, highlighting the importance of ongoing research in developing new and effective treatments.